Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-08-08 |
2024-06 |
-0.32 |
N/A |
N/A |
N/A |
2024-05-09 |
2024-03 |
-0.24 |
-0.27 |
-0.03 |
-12.50% |
2024-03-14 |
2023-12 |
-0.25 |
-0.3 |
-0.05 |
-20.00% |
2023-11-14 |
2023-09 |
-0.23 |
-0.21 |
0.02 |
8.70% |
2023-08-10 |
2023-06 |
-0.21 |
-0.19 |
0.02 |
9.52% |
2023-05-15 |
2023-03 |
-0.25 |
-0.15 |
0.1 |
40.00% |
Date |
Firm |
Action |
From |
To |
2023-08-14 |
JMP Securities |
Upgrade |
Market Outperform |
Market Outperform |
2023-05-17 |
Citigroup |
Upgrade |
Neutral |
Neutral |
2023-05-16 |
Guggenheim |
Upgrade |
Buy |
Buy |
2023-05-15 |
JMP Securities |
Upgrade |
Market Outperform |
Market Outperform |
2023-05-14 |
Citigroup |
Upgrade |
Neutral |
Neutral |
2023-03-14 |
Guggenheim |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2024-01-16 |
BEN MAIMON CAROLE S |
Chief Executive Officer |
332.95K |
Stock Award(Grant) |
2024-01-16 |
CELANO MICHAEL |
Chief Financial Officer |
144.00K |
Stock Award(Grant) |
2024-01-16 |
CLAYTON RUSSELL |
Officer |
22.50K |
Stock Award(Grant) |
2024-02-15 |
FLYNN JAMES E |
Director and Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Purchase |
2024-02-15 |
HAMILTON THOMAS EDWARD |
Director |
724.23K |
Purchase |
2019-01-23 |
LAMATTINA JOHN L |
Director |
31.38K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Deerfield Management Company, L.P. (Series C) |
16.94M |
53.03M |
39.15% |
2023-06-29 |
Chi Advisors Llc |
3.41M |
10.69M |
7.89% |
2023-06-29 |
Verition Fund Management, LLC |
2.72M |
8.50M |
6.28% |
2023-06-29 |
Woodline Partners LP |
1.68M |
5.26M |
3.89% |
2023-06-29 |
Janus Henderson Group PLC |
1.45M |
4.53M |
3.34% |
2023-06-29 |
Blackrock Inc. |
1.44M |
4.50M |
3.32% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
853.03K |
2.67M |
1.97% |
2023-08-30 |
iShares Russell 2000 ETF |
503.72K |
1.87M |
1.16% |
2023-06-29 |
Vanguard Extended Market Index Fund |
392.62K |
1.23M |
0.91% |
2023-07-30 |
Fidelity Small Cap Index Fund |
225.36K |
964.52K |
0.52% |
2023-08-30 |
iShares Russell 2000 Value ETF |
210.62K |
783.51K |
0.49% |
2023-05-30 |
Fidelity Extended Market Index Fund |
153.20K |
565.31K |
0.35% |
Split |
Date |
1 : 12 |
2020-05-29 |